Biotech startup OccuRx raises $16 million for kidney disease trial
Biotech startup OccuRx has raised $16 million to fund clinical phase studies for its oral therapy to treat chronic kidney disease (CKD), a leading cause of death. The round was jointly led by Brandon BioCatalyst and Uniseed and also includes a $1.5 million grant from biomedical incubator CUREator. The funding will be used for a… Read more »